Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacyclonol SCHEMBL6135637 | 0.98 | HRH1 (0.96) | HRH1CYP2D6LMNAMEN1SCN1A | |
| Azacyclonol SCHEMBL1890138 | 0.98 | HRH1 (0.96) | HRH1CYP2D6LMNAMEN1SCN1A | |
| Azacyclonol SCHEMBL1648657 | 0.96 | HRH1 (0.93) | HRH1CYP2D6LMNAMEN1SCN1A | |
| Azacyclonol SCHEMBL27517195 | 0.91 | HRH1 (0.83) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL11395372 | 0.91 | CYP2D6 (0.83) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL11831606 | 0.90 | HRH1 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL7328353 | 0.90 | CYP2D6 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL11832155 | 0.90 | CYP2D6 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL13923571 | 0.90 | HRH1 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL11835095 | 0.90 | CYP2D6 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2024263560-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024207016-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. (US) | 2024-10-03 | — | — | WO | claimed |
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | claimed |
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-09-01 | — | — | US | claimed |
| EP-3651759-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | Syneurx International (Taiwan) Corp. (TW) | 2020-05-20 | — | — | EP | claimed |
| EP-3635130-A1 | PRECISION MEDICINE FOR TREATING AND PREVENTING SUICIDALITY | Indiana University Research and Technology Corporation (US) | 2020-04-15 | — | — | EP | claimed |
| WO-2002010115-A1 | NEW PROCESSES FOR THE PRODUCTION OF FEXOFENADINE | TEXCONTOR ETABLISSEMENT (LI) | 2002-02-07 | — | — | WO | claimed |
| US-6147217-A | Synthesis of terfenadine and derivatives | SEPRACOR INC. (US) | 2000-11-14 | — | — | US | claimed |
| US-5925761-A | Synthesis of terfenadine and derivatives | SEPRACOR INC. (US) | 1999-07-20 | — | — | US | claimed |
| US-5777125-A | Process for the preparation of tertiary carbinols containing an amino substituent | GRUPPO LEPETIT SPA (IT) | 1998-07-07 | — | — | US | claimed |
| EP-0815860-A2 | Terfenadine carboxylate and the treatment of allergic disorders | SEPRACOR, INC. (US) | 1998-01-07 | — | — | EP | claimed |
| EP-0648759-A1 | Antihistaminic compounds, process for their preparation and pharmaceutical compositions containing them | ERREGIERRE S.p.A. (IT) | 1995-04-19 | — | — | EP | claimed |
| EP-0641322-A1 | PROCESSES FOR PRODUCING $g(a)-PYRIDYL CARBINOLS | REILLY INDUSTRIES, INC. (US) | 1995-03-08 | — | — | EP | claimed |
| US-5347006-A | Method of preparing a polymorph of terfenadine | LAVACCHIELLI AUGUSTO (IT) | 1994-09-13 | — | — | US | claimed |
| WO-1992019596-A2 | PROCESSES FOR PRODUCING α-PYRIDYL CARBINOLS | REILLY INDUSTRIES, INC. (US) | 1992-11-12 | — | — | WO | claimed |
| US-5043396-A | Novel crosslinked polymer having shape memorizing property, method of its use, and molded article having shape memory | NIPPON ZEON CO., LTD. (JP) | 1991-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SLC1A2, SLC6A5, SLC1A1 | HRH1 809/4885CYP2D6 778/4885LMNA 2385/4885 |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | NOS2, NOS1, NOS3 | HRH1 1828/4885CYP2D6 101/4885LMNA 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.